AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenos… Read more
AgomAb Therapeutics NV American Depositary Shares (AGMB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.066x
Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has a cash flow conversion efficiency ratio of -0.066x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.44 Million) by net assets ($188.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AgomAb Therapeutics NV American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AgomAb Therapeutics NV American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tadir-Gan (Precision Products) 1993 Ltd
TA:TDGN
|
-0.009x |
|
Danske Invest Euro Investment Grade-Obligationer
CO:DKIEIGO
|
N/A |
|
Archon Corporation
PINK:ARHN
|
-0.012x |
|
All Things Mobile Analytic Inc
PINK:ATMH
|
0.004x |
|
Cirsa Enterprises SAU
MC:CIRSA
|
N/A |
|
Jyske Invest Virksomhedsobligationer
CO:JYIVIRK
|
N/A |
|
ARROWSTAR RESOURCES
F:D2E
|
-0.004x |
|
HERBALIFE
MU:HOO
|
-0.104x |
Annual Cash Flow Conversion Efficiency for AgomAb Therapeutics NV American Depositary Shares (2022–2024)
The table below shows the annual cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $188.08 Million | $-46.83 Million | -0.249x | -53.32% |
| 2023-12-31 | $151.44 Million | $-24.59 Million | -0.162x | +43.28% |
| 2022-12-31 | $66.25 Million | $-18.97 Million | -0.286x | -- |